IBIO Archives - Page 7 of 8

Developments

iBio Joins the Alliance for Biosecurity

iBio (NYSE AMERICAN:IBIO) joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies, along with laboratory and academic partners, that promote a strong public-private partnership in order to ensure...

March 20, 2020

Developments

iBio making progress with its COVID-19 vaccine candidates

iBio (NYSE AMERICAN:IBIO) reported progress toward developing vaccine candidates for SARS-CoV-2, the coronavirus that causes COVID-19. In a matter of a few weeks, the company used its FastPharming system to create SARS...

March 18, 2020

Executive Moves

iBio appoints accomplished life sciences executive, Thomas Isett, as co-chairman and CEO

Thomas Isett iBio (NYSE AMERICAN:IBIO) appointed Thomas Isett, a current iBio board member, as its co-chairman and CEO. Mr. Isett succeeds Robert Kay, who has retired from the role of CEO, but will remain as co-chairman...

March 12, 2020

Developments

iBio and CC-Pharming to develop coronavirus vaccine

iBio (NYSE AMERICAN:IBIO) and CC-Pharming are expanding the scope of their partnership with the planned development of a new 2019-nCoV vaccine to be manufactured using iBio’s FastPharming system. The companies aim to...

February 3, 2020

Developments

iBio initiates new litigation against Fraunhofer

iBio (NYSE AMERICAN:IBIO) filed a motion in the Court of Chancery of the State of Delaware to initiate new litigation against Fraunhofer-Gesellschaft through an amended complaint. The new motion asserts that depositions...

January 6, 2020

Developments

iBio reports progress on bio-better rituximab collaboration

At last week’s Antibody Engineering & Therapeutics conference in San Diego, CA, iBio (NYSE AMERICAN:IBIO) presented its glycan engineering technologies and plant-based manufacturing platform as a means to rapidly...

December 16, 2019

Developments

iBio unveils FastGlycaneering Development Service to produce recombinant proteins

iBio (NYSE AMERICAN:IBIO) unveiled its FastGlycaneering Development Service, which includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Biopharmaceutical innovators...

December 11, 2019

Markets

Dawson James starts CollPlant Biotechnologies at buy; PT $9

Dawson James Securities initiated coverage of CollPlant Biotechnologies (NASDAQ:CLGN) with a “buy” rating and $9 price target. The stock closed at $4.62 on Nov. 1. CollPlant’s technology platform mass produces...

November 4, 2019

Developments

iBio expands collaboration with AzarGen to develop plant-made rituximab

iBio (NYSE AMERICAN:IBIO) advanced its collaboration with closely-held AzarGen Biotechnologies by initiating development of a plant-made rituximab for the South African market. iBio previously used its FastPharming...

September 17, 2019

Developments

iBio and CC-Pharming expand biopharma business collaboration in China

iBio (NYSE AMERICAN:IBIO) granted partner CC-Pharming an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab product candidates in China.

August 27, 2019

Tag - IBIO

iBio Joins the Alliance for Biosecurity

iBio making progress with its COVID-19 vaccine candidates

iBio appoints accomplished life sciences executive, Thomas Isett, as co-chairman and CEO

iBio and CC-Pharming to develop coronavirus vaccine

iBio initiates new litigation against Fraunhofer

iBio reports progress on bio-better rituximab collaboration

iBio unveils FastGlycaneering Development Service to produce recombinant proteins

Dawson James starts CollPlant Biotechnologies at buy; PT $9

iBio expands collaboration with AzarGen to develop plant-made rituximab

iBio and CC-Pharming expand biopharma business collaboration in China

General

More